Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc.RARE · Entity 4337 | Director · President & CEO | April 16, 2026 | April 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ultragenyx Pharmaceutical Inc.
Report date April 16, 2026 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 735,739 |
Reported balance
After 2026-04-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-04-16 · Grant · Acquired 76,745 · Balance 735,739 F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date F2: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.52 · Expires 2036-04-16 | Direct | 132,693 |
Reported balance
After 2026-04-16 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2026-04-16 · Grant · Acquired 132,693 · Balance 132,693 F4: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. |
| Common StockSEC Table I · non-derivative | IndirectBy Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 200909 | 1,758,985 |
Reported balance
Holding disclosure · report date 2026-04-16 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 1,758,985 F3: Amount of securities beneficially owned following reported transaction reflects the contribution of an aggregate of 400,000 shares previously owned indirectly by the reporting person to two grantor retained annuity trusts (each, a "GRAT"). |
| Common StockSEC Table I · non-derivative | IndirectBy GRAT | 200,000 |
Reported balance
Holding disclosure · report date 2026-04-16 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 200,000 |
| Common StockSEC Table I · non-derivative | IndirectBy GRAT | 200,000 |
Reported balance
Holding disclosure · report date 2026-04-16 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 200,000 |
Filing footnotes · ownership attribution and instrument terms
F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
F2: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
F3: Amount of securities beneficially owned following reported transaction reflects the contribution of an aggregate of 400,000 shares previously owned indirectly by the reporting person to two grantor retained annuity trusts (each, a "GRAT").
F4: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 06, 2020 Filed May 9, 2020 00:06 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 852 | $66.26 | $56,453.52 |
DisclosureSEC source: 0001209191-20-028114 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 652,797 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| April 19, 2020 Filed Apr 21, 2020 19:34 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 851 | $58.57 | $49,843.07 |
DisclosureSEC source: 0001209191-20-025189 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 653,649 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units ("RSUs"). F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 12, 2020 Filed Mar 13, 2020 16:59 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | OtherWarrant (Right to Buy) · Derivative | 66,533 | $0.00 Strike: $3.01 | $0.00 |
DisclosureSEC source: 0001209191-20-018749 · doc4.xml · derivative · entry 5 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 66,533 shares Expires 2021-06-14 Read SEC document |
| March 12, 2020 Filed Mar 13, 2020 16:59 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | OtherWarrant (Right to Buy) · Derivative | 83,167 | $0.00 Strike: $3.01 | $0.00 |
DisclosureSEC source: 0001209191-20-018749 · doc4.xml · derivative · entry 4 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 83,167 shares Expires 2020-06-30 Read SEC document |
| March 12, 2020 Filed Mar 13, 2020 16:59 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | OtherCommon Stock | 66,533 | $3.01 | $199,998.20 |
DisclosureSEC source: 0001209191-20-018749 · doc4.xml · nonDerivative · entry 2 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 654,500 F1 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 12, 2020 Filed Mar 13, 2020 16:59 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | OtherCommon Stock | 83,167 | $3.01 | $250,000.00 |
DisclosureSEC source: 0001209191-20-018749 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 587,967 F1 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:58 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 56,100 | $0.00 Strike: $56.08 | $0.00 |
DisclosureSEC source: 0001209191-20-015760 · doc4.xml · derivative · entry 5 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,100 Underlying: Common Stock · 56,100 shares Expires 2030-03-01 F5 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:58 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 6,896 | $56.08 | $386,727.68 |
DisclosureSEC source: 0001209191-20-015760 · doc4.xml · nonDerivative · entry 3 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 504,800 F4 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:58 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 18,782 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015760 · doc4.xml · nonDerivative · entry 2 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 511,696 F3 · shares: Represents 6,198 shares of common stock and 12,584 RSUs which previously granted performance stock units were converted on March 1, 2020 upon certification of the performance metric. The RSUs will fully vest on March 1, 2021. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2020 Filed Mar 4, 2020 00:58 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 17,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-015760 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 492,914 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| October 14, 2019 Filed Oct 16, 2019 23:30 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 3,435 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-053326 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 475,914 F1 · shares: Represents restricted stock units (RSUs) into which previously granted performance stock units were converted on October 14, 2019 upon certification of the applicable performance metric. Half of these RSUs will vest on the first anniversary of the certification date and the other half will vest on the second anniversary of the certification date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| September 11, 2019 Filed Sep 11, 2019 16:35 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | PurchaseCommon Stock | 5,000 | $43.63 | $218,150.00 |
DisclosureSEC source: 0001209191-19-049117 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 472,479 Read SEC document |
| June 01, 2019 Filed Jun 4, 2019 22:59 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 1,327 | $54.93 | $72,892.11 |
DisclosureSEC source: 0001209191-19-034552 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 467,479 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| May 21, 2019 Filed May 22, 2019 21:44 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 1,414 | $59.50 | $84,133.00 |
DisclosureSEC source: 0001209191-19-032138 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 468,806 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| May 06, 2019 Filed May 7, 2019 22:57 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 3,435 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-028093 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,220 F1 · shares: Represents restricted stock units (RSUs) into which previously granted performance stock units were converted on May 6, 2019 upon certification of the applicable performance metric. Half of these RSUs will vest on the first anniversary of the certification date and the other half will vest on the second anniversary of the certification date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| April 19, 2019 Filed Apr 23, 2019 22:41 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 798 | $64.43 | $51,415.14 |
DisclosureSEC source: 0001209191-19-025622 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 466,785 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 05, 2019 Filed Apr 17, 2019 21:38 UTC Amendment | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 2,890 | $65.52 | $189,352.80 |
DisclosureSEC source: 0001209191-19-025069 · doc4a.xml · nonDerivative · entry 2 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 467,583 F3 · shares: Represents shares sold to pay required tax withholdings due to the vesting of Restricted Stock Units. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:00 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 66,000 | $0.00 Strike: $67.55 | $0.00 |
DisclosureSEC source: 0001209191-19-015726 · doc4.xml · derivative · entry 4 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,000 Underlying: Common Stock · 66,000 shares Expires 2029-03-01 F4 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:00 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 2,802 | $67.55 | $189,275.10 |
DisclosureSEC source: 0001209191-19-015726 · doc4.xml · nonDerivative · entry 2 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 467,670 F3 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. Read SEC document |
| March 01, 2019 Filed Mar 4, 2019 22:00 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-015726 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,472 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2019 Filed Apr 17, 2019 21:38 UTC Amendment | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 66,000 | $0.00 Strike: $67.55 | $0.00 |
DisclosureSEC source: 0001209191-19-025069 · doc4a.xml · derivative · entry 4 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,000 Underlying: Common Stock · 66,000 shares Expires 2029-03-01 F4 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2019 Filed Apr 17, 2019 21:38 UTC Amendment | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-025069 · doc4a.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 470,473 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| June 01, 2018 Filed Jun 4, 2018 20:45 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 926 | $73.73 | $68,273.98 |
DisclosureSEC source: 0001209191-18-035161 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,472 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| May 21, 2018 Filed May 22, 2018 15:42 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 986 | $64.79 | $63,882.94 |
DisclosureSEC source: 0001209191-18-032206 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 451,398 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| April 19, 2018 Filed Apr 19, 2018 20:42 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 3,429 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-025586 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 452,384 F1 · shares: Represents restricted stock units (RSUs) into which previously granted performance stock units were converted on April 19, 2018 upon certification of the applicable performance metric. Half of these RSUs will vest on the first anniversary of the certification date and the other half will vest on the second anniversary of the certification date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:12 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 94,500 | $0.00 Strike: $48.43 | $0.00 |
DisclosureSEC source: 0001209191-18-016405 · doc4.xml · derivative · entry 4 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 94,500 Underlying: Common Stock · 94,500 shares Expires 2028-03-01 F4 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:12 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 1,114 | $48.43 | $53,951.02 |
DisclosureSEC source: 0001209191-18-016405 · doc4.xml · nonDerivative · entry 2 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 448,955 F3 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:12 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 19,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-016405 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 450,069 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| August 28, 2017 Filed Aug 29, 2017 20:30 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | PurchaseCommon Stock | 1,647 | $52.96 | $87,225.12 |
DisclosureSEC source: 0001209191-17-050586 · doc4.xml · nonDerivative · entry 2 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009 Disclosed balance after: 2,559,741 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $52.90 to $52.99 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| August 28, 2017 Filed Aug 29, 2017 20:30 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | PurchaseCommon Stock | 5,853 | $52.40 | $306,697.20 |
DisclosureSEC source: 0001209191-17-050586 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Emil Kakkis and Jenny Soriano Living Trust, dated June 18, 2009 Disclosed balance after: 2,558,094 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $51.89 to $52.88 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 01:14 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 1,006 | $56.61 | $56,949.66 |
DisclosureSEC source: 0001209191-17-036973 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 430,569 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units. Read SEC document |
| May 21, 2017 Filed May 22, 2017 23:04 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 1,072 | $57.47 | $61,607.84 |
DisclosureSEC source: 0001209191-17-034491 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 431,575 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 22:42 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantEmployee Stock Option (Right to Buy) · Derivative | 78,000 | $0.00 Strike: $88.80 | $0.00 |
DisclosureSEC source: 0001209191-17-016065 · doc4.xml · derivative · entry 3 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,000 Underlying: Common Stock · 78,000 shares Expires 2027-03-01 F3 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 22:42 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 13,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-016065 · doc4.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 432,647 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| December 22, 2016 Filed Feb 10, 2017 23:00 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GiftCommon Stock | 27,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-009699 · doc5.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 419,647 Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 21:01 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 200 | $83.01 | $16,602.00 |
DisclosureSEC source: 0001562180-16-003561 · primarydocument.xml · nonDerivative · entry 5 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 447,147 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $83.00 to $83.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 21:01 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 4,180 | $82.36 | $344,264.80 |
DisclosureSEC source: 0001562180-16-003561 · primarydocument.xml · nonDerivative · entry 4 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 447,347 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.00 to $82.95 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 21:01 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 7,755 | $81.55 | $632,420.25 |
DisclosureSEC source: 0001562180-16-003561 · primarydocument.xml · nonDerivative · entry 3 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 451,527 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $81.00 to $81.98 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 21:01 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 6,451 | $80.64 | $520,208.64 |
DisclosureSEC source: 0001562180-16-003561 · primarydocument.xml · nonDerivative · entry 2 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 459,282 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $79.97 to $80.955 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| November 15, 2016 Filed Nov 17, 2016 21:01 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 1,414 | $79.39 | $112,257.46 |
DisclosureSEC source: 0001562180-16-003561 · primarydocument.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 465,733 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $78.97 to $79.74 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 14, 2016 Filed Oct 18, 2016 20:01 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 1,800 | $64.78 | $116,604.00 |
DisclosureSEC source: 0001562180-16-003247 · primarydocument.xml · nonDerivative · entry 4 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 467,147 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.67 to $64.91 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 14, 2016 Filed Oct 18, 2016 20:01 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 2,345 | $64.41 | $151,041.45 |
DisclosureSEC source: 0001562180-16-003247 · primarydocument.xml · nonDerivative · entry 3 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 468,947 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.65 to $64.64 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 14, 2016 Filed Oct 18, 2016 20:01 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 9,340 | $63.06 | $588,980.40 |
DisclosureSEC source: 0001562180-16-003247 · primarydocument.xml · nonDerivative · entry 2 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 471,292 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $62.57 to $63.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| October 14, 2016 Filed Oct 18, 2016 20:01 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | SaleCommon Stock | 6,515 | $61.97 | $403,734.55 |
DisclosureSEC source: 0001562180-16-003247 · primarydocument.xml · nonDerivative · entry 1 KAKKIS EMIL D · CIK 0001248093 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 480,632 F1 · kind: The sales reported on this Form 4 were effected pursuant to a trading plan adopted by the Reporting Person pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $61.57 to $62.56 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.